Amedisys (AMED) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive
November 7, 2016 7:48 AM ESTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $47.00, calling the sell-off after the COO resigned 'excessively overdone'.
Analyst Sheryl Skolnick commented, "AMED's shares dove Friday in concert with another C-Suite change at the... More
Amedisys (AMED) PT Cut to $47 at Mizuho Following Results
November 4, 2016 7:05 AM EDTMizuho Securities analyst Sheryl Skolnick reiterated a Neutral rating and lowered her price target on Amedisys (NASDAQ: AMED) to $47.00 following results.
Skolnick commented, "What the new team has done for AMED in a very short period of time seems close to a miracle... More
